Open access · CC-BY
via OpenAlex
Challenges in developing Geroscience trials
Yves Rolland, Felipe Sierra, Luigi Ferrucci, Nir Barzilai, Rafael de Cabo, Joan B. Mannick, Anthony A. Oliva, William J. Evans, Davide Angioni, Philipe de Souto Barreto, Jérémy Raffin, Bruno J. Vellas, James L. Kirkland, the G.C.T-TF group, Sandrine Andrieu
Nature Communications · 2023 · ▲ 90 citations
Abstract
Geroscience is becoming a major hope for preventing age-related diseases and loss of function by targeting biological mechanisms of aging. This unprecedented paradigm shift requires optimizing the design of future clinical studies related to aging in humans. Researchers will face a number of challenges, including ideal populations to study, which lifestyle and Gerotherapeutic interventions to test initially, selecting key primary and secondary outcomes of such clinical trials, and which age-related biomarkers are most valuable for both selecting interventions and predicting or monitoring clinical responses ("Gerodiagnostics"). This article reports the main results of a Task Force of experts in Geroscience.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.1038/s41467-023-39786-7
- Canonical
- link ↗
- Fetched
- 2026-09-22 MST
Cite this
APA
Rolland, Y., Sierra, F., Ferrucci, L., Barzilai, N., Cabo, R.D., Mannick, J.B., Oliva, A.A., Evans, W.J., Angioni, D., Barreto, P.D.S., Raffin, J., Vellas, B.J., Kirkland, J.L., group, T.G., Andrieu, S., Bacqueville, D., Bischoff-Ferrari, H.A., Blivet, G., Cash, T.P., & Cuervo, A. (2023). Challenges in developing Geroscience trials. <em>Nature Communications</em>. https://doi.org/10.1038/s41467-023-39786-7
Vancouver
Rolland Y, Sierra F, Ferrucci L, Barzilai N, Cabo RD, Mannick JB, et al. Challenges in developing Geroscience trials. Nature Communications. 2023. doi:10.1038/s41467-023-39786-7.
BibTeX
@article{yves2023Challe,
title = {Challenges in developing Geroscience trials},
author = {Yves Rolland and Felipe Sierra and Luigi Ferrucci and Nir Barzilai and Rafael de Cabo and Joan B. Mannick and Anthony A. Oliva and William J. Evans and Davide Angioni and Philipe de Souto Barreto and Jérémy Raffin and Bruno J. Vellas and James L. Kirkland and the G.C.T-TF group and Sandrine Andrieu and Daniel Bacqueville and Heike Annette Bischoff-Ferrari and Guillaume Blivet and Timothy P. Cash and Ana-Maria Cuervo and Noélie Davezac and Andrea Dimet‐Wiley and Alexander Fleming and Friedlander Gérard and Mitzi M. Gonzales},
journal = {Nature Communications},
year = {2023},
doi = {10.1038/s41467-023-39786-7},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
The Journals of Gerontology Series A 2016
Open access · CC-BY
Frameworks for Proof-of-Concept Clinical Trials of Interventions That Target Fundamental Aging Processes
bioRxiv (Cold Spring Harbor Laboratory) 2025
Preprint · CC-BY
SGLT2 Inhibition Ameliorates Age-Dependent Renovascular Rarefaction
European Journal of Public Health 2021
Citation only
The future of healthy aging: translation of geroscience discoveries to public health practice
Kidney International 2025
Open access · CC-BY
Sodium-glucose co-transporter 2 inhibition improves age-dependent kidney microvascular rarefaction
Kidney international 2026
Open access · OA
Sodium-glucose co-transporter 2 inhibition improves age-dependent kidney microvascular rarefaction.
Fertility and Sterility 2013
Open access · OA